MethylGene Inc. (TSX:MYG) today announced the closing of its previously announced bought deal public offering of 5,500,000 common shares. The offering was made through a syndicate of underwriters led by Canaccord Capital Corporation and including Blackmont Capital Inc., Raymond James Ltd. and Clarus Securities Inc.
